Increasing burden of cardiovascular disease: Current knowledge and future directions for research on risk factors

Circulation

Volumn 97, Issue 11, 1998, Pages 1095-1102

  Hennekens, Charles H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cardiovascular diseases; Epidemiology; Risk factors; Trials

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; HEART DISEASE; MORTALITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; FEMALE; FORECASTING; HUMANS; MALE; RESEARCH; RISK FACTORS; UNITED STATES;

EID: 0032562263     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.11.1095     Document Type: Article

References (67)

1. Conner LA. The American Heart Journal. Am Heart J. 1925;1:115-116.
2. Statistical Abstract of the United States: 1995. Washington, DC: US Department of Commerce; 1995.
3. Hennekens CH, Buring JE. Epidemiology in Medicine. Boston, Mass: Little, Brown & Co; 1987.
4. Total Population Death Rate for CVD, by Age, per 100 000, US, 1979-93. Dallas, Tex: American Heart Association; 1996.
5. Health, United States, 1994. Hyattsville, Md: National Center for Health Statistics; 1995.
6. Johnson LD, Bachman JG, O'Malley PM. Cigarette Smoking Continues to Rise Among American Teenagers in 1996. Ann Arbor, Mich: University of Michigan News and Information Services; December 19, 1996.
7. Troiano RP, Flegal KM, Kuczmarski RJ, Campbell SM, Johnson CL. Overweight prevalence and trends for children and adolescents. Arch Pediatr Adolesc Med. 1995;149:1084-1091.
8. Physical Activity and Health: A Report of the Surgeon General. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1996.
9. Murray CJL, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Cambridge, Mass: Harvard University Press; 1996.
10. Murray CJL, Lopez AD. The Global Burden of Disease: Summary. Cambridge, Mass: Harvard University Press; 1996.
11. Cairns J. The treatment of diseases and the war against cancer. Sci Am. 1985;253:51-59.
12. Hennekens CH, Buring JE. Observational evidence. In: Warren KS, Mosteller F, eds. Doing More Good than Harm: The Evaluation of Health Care Interventions. Ann N Y Acad Sci. 1993;703:18-24.
13. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease, 1: prolonged differences in blood pressure - prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335: 765-774.
14. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease, 2: short-term reductions in blood pressure: overview of randomized drug trials in their epidemiologic context. Lancet. 1990;335:827-838.
15. Hebert PR, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.
16. Doll R, Hill AB. Smoking and carcinoma of the lung: preliminary report. BMJ. 1950;2:739-748.
17. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: a study of 684 proved cases. JAMA. 1950;143: 329-336.
18. Smoking and Health: Report of the Advisory Committee to the Surgeon General of the Public Health Service. Washington, DS: US Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control; 1964. PHS publication No. 1103.
19. Hennekens CH, Buring J, Mayrent SL. Smoking and aging in coronary heart disease. In: Bosse R, Rose C, eds. Smoking and Aging. Lexington, Mass: DC Heath; 1984:95-115.
20. Hennekens CH, Gaziano JM, Manson JE, Buring JE. Antioxidant vitamin-cardiovascular disease hypothesis is still promising, but still unproven: the need for randomized trials. Am J Clin Nutr. 1995;62:1337S-1380S.
21. Blot WJ, Li JY, Taylor PR, Guo W, Dawsey S, Wang GQ, Yang CS, Zheng SF, Gail M, Li GY, Yu Y, Liu Bq, Tangrea J, Sun Yh, Liu F, Fraumeni JF, Zhang YH, Li B. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85:1483-1492.
22. Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330:1029-1035.
23. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Branhard S, Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-1155.
24. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-1149.
25. Worth RM, Kato H, Rhoads GG, Kagan A, Syme SL. Epidemiologic studies of coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: mortality. Am J Epidemiol. 1975;102:481-490.
26. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, Buring JE, Hennekens CH. The primary prevention of myocardial infarction. N Engl J Med. 1992;326:1406-1416.
27. Heller RF, Chinn S, Tunstall Pedoe HD, Rose G. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. BMJ. 1984;288:1409-1411.
28. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
29. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80:749-756.
30. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged anti-platelet therapy. BMJ. 1988;296:320-332.
31. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet treatment, I: prevention of vascular death, myocardial infarction and stroke by prolonged antiplatelet therapy in different categories of patients. BMJ. 1994;308:81-106.
32. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
33. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
34. Buring JE, Hennekens CH, for the Women's Health Study Research Group. The Women's Health Study: summary of the study design. J Myocardial Ischemia. 1992;4:27-29.
35. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756-762.
36. Rich-Edwards J, Manson JK, Hennekens CH, Buring JE. Primary prevention of coronary heart disease in women. N Engl J Med. 1995;332: 1758-1766.
37. Braunwald E. Foreword. In: Fuster V, Verstraete M, eds. Thrombosis and Cardiovascular Disease. Philadelphia, Pa: WB Saunders; 1992.
38. Ridker PM, Hennekens CH. Hemostatic risk factors for coronary heart disease. Circulation. 1991;83:1098-1100.
39. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;7:878-881.
40. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R. Methylenetetrahydrofolate reductase polymorphism plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996;94:2410-2416.
41. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984;311:501-505.
42. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986;2:533-537.
43. Goldbourt U, Behar S, Reicher-Reiss H, Agmon J, Kaplinsky E, Graff E, Kishon Y, Caspi A, Weisbort J, Mandelzweig L. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Study). Am J Cardiol. 1993;71:909-915.
44. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
45. Van der Poll T, Levi M, Hack CE, ten Cate H, van Deventer SJH, Evenberg AJM, de Groot ER, Jansen J, Gallati H, Büller HR, ten Cate JW, Aarden LA. Elimination of interleukin-6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med. 1994;179: 1253-1259.
46. Hardardottir I, Grunfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol. 1994;5:207-215.
47. Ioamoto GK, Konicel SA. Cytomegalovirus immediate early genes upregulate interleukin-6 gene expression. J Invest Med. 1997;45:175-182.
48. Örtqvist Å, Hedlund J, Wretling B, Carlström A, Kalin M. Diagnostic and prognostic values of interleukin-6 and C-reactive protein in community-acquired pneumonia. Scand J Infect Dis. 1995;27:457-462.
49. Cohen HJ, Pieper CF, Harris TB, Rao KMK, Currie MS. Associations of plasma IL-6 levels with functional disability in community-dwelling elderly. J Gerontol Med Sci. In press.
50. Hotamisgil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor-necrosis factor-α in human obesity and insulin resistance. J Clin Invest. 1995;95:2409-2415.
51. Takahashi K, Takashiba S, Nagai A, Takigawa M, Myoukai F, Kurihara H, Murayama Y. Assessment of interleukin-6 in the pathogenesis of periodontal disease. J Periodontal Res. 1994;65:147-153.
52. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med. 1995;332:848-854.
53. Meydani M, Evans WJ, Handelman G, Biddle L, Fielding RA, Meydani SN, Burrill J, Fiatarone MA, Blumber JB, Cannon JG. Protective effect of vitamin E on exercise-induced oxidative damage in young and older adults. Am J Physiol. 1993;264:R992-R998.
54. DeRijk R, Michelson D, Karp B, Petrides J, Galliven E, Deuster P, Paciotti G, Gold PW, Sternberg EM. Exercise and circadian rhythm-induced variations in plasma cortisol differentially regulate interleukin-1β, IL-6, and tumor necrosis factor-α production in humans: high sensitivity of TNF-α and resistance of IL-6. J Clin Endocrinol Metab. 1997;82:2182-2191.
55. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
56. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JM, Packard CJ. Prevention ot coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Primary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
57. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335: 1001-1009.
58. Heben PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. JAMA. 1997;278: 313-321.
59. LaCroix AZ, Lang J, Scherr P, Wallace RB, Cornoni-Huntley J, Berkman L, Curb JD, Evans D, Hennekens CH. Smoking and mortality among older men and women in three communities. N Engl J Med. 1991;324: 1619-1625.
60. Manson JE, Stampfer MJ, Hennekens CH, Willett WC. Body weight and longevity: a reassessment. JAMA. 1987;257:353-358.
61. Manson JE, Willett WC, Stampfer MJ, Colditz GA, Hunter DJ, Hankinson SE, Hennekens CH, Speizer FE. Body weight and mortality among women. N Engl J Med. 1995;333:677-685.
62. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, Hennekens CH. Weight and weight change in relation to risk of coronary heart disease in women: a 14-year follow-up. JAMA. 1995;273:461-465.
63. Women's top health risks. U S A Today. May 18, 1995:1-D.
64. Breslow J. Presidential address. Presented at the American Heart Association 69th Scientific Sessions, November 10, 1996, New Orleans, La.
65. Bush V. Science: the endless frontier: a report to the President by Vannevar Bush, director of the Office of Scientific Research and Development. Washington, DC: US Government Printing Office; July 1945.
66. Rudenstine NL. Don't slash funding for scientific research. The Boston Globe. July 11, 1995.
67. Bartlett J. Famous Quotations: A Collection of Passages, Phrases, and Proverbs Traced to Their Sources in Ancient and Modern Literature. 16th ed. Boston, Mass: Little, Brown and Co; 1992:310.